155TiP A randomised phase II trial of neoadjuvant multi-agent chemotherapy (CHT) OR patritumab deruxtecan (HER3-DXd; U3-1402) +/- endocrine therapy (ET) for high-risk hormone receptor-positive (HR+/HER2-) early breast cancer (EBC): SOLTI-2103 VALENTINE trial

Authors :: M. Oliveira
T. Pascual
G. Villacampa
M. Munoz
A. Perello Martorell
M.E. Perez Lopez
K. Amillano Parraga
X. González Farre
C. Martinez Vila
P. Tolosa Ortega
M. Borrell Puy
M. Margeli Vila
J.M. Cejalvo
Y. Zheteyava
D.W. Sternberg
P.D. Fan
A. Santhanagopal
R. Sanchez Bayona
J.M. Ferrero-Cafiero
A. Prat
Source :: ESMO Open. 8:101494
Publication Year :: 2023
Publisher :: Elsevier BV, 2023.

Full Text Access

Tools